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he evolution of mitogenic pathways has led to the
parallel requirement for negative control mechanisms,
which prevent aberrant growth and the development
of cancer. Principally, such negative control mechanisms
are represented by tumor suppressor genes, which normally
 
act to constrain cell proliferation (Macleod, K. 2000. 
 
Curr
 
.
 
Opin
 
. 
 
Genet
 
. 
 
Dev
 
. 10:81–93). Tuberous sclerosis complex
(TSC) is an autosomal-dominant genetic disorder, character-
ized by mutations in either TSC1 or TSC2, whose gene
products hamartin (TSC1) and tuberin (TSC2) constitute a
 
putative tumor suppressor complex (TSC1-2; van Slegtenhorst,
M., M. Nellist, B. Nagelkerken, J. Cheadle, R. Snell, A. van
den Ouweland, A. Reuser, J. Sampson, D. Halley, and P.
 
van der Sluijs. 1998. 
 
Hum
 
. 
 
Mol
 
. 
 
Genet
 
. 7:1053–1057). Little
is known with regard to the oncogenic target of TSC1-2,
however recent genetic studies in 
 
Drosophila
 
 have shown
that S6 kinase (S6K) is epistatically dominant to TSC1-2
T
 
(Tapon, N., N. Ito, B.J. Dickson, J.E. Treisman, and I.K.
Hariharan. 2001. 
 
Cell
 
. 105:345–355; Potter, C.J., H.
Huang, and T. Xu. 2001. 
 
Cell
 
. 105:357–368). Here we
show that loss of TSC2 function in mammalian cells leads
to constitutive S6K1 activation, whereas ectopic expression
of TSC1-2 blocks this response. Although activation of
wild-type S6K1 and cell proliferation in TSC2-deﬁcient
cells is dependent on the mammalian target of rapamycin
(mTOR), by using an S6K1 variant (GST-
 
 
 
C-S6K1), which is
uncoupled from mTOR signaling, we demonstrate that
TSC1-2 does not inhibit S6K1 via mTOR. Instead, we show
by using wortmannin and dominant interfering alleles of
phosphatidylinositide-3-OH kinase (PI3K) that increased
S6K1 activation is contingent upon the suppression of TSC2
function by PI3K in normal cells and is PI3K independent
in TSC2-deﬁcient cells.
 
Introduction
 
Tuberous sclerosis complex (TSC)* is characterized by
mutations in either TSC1 or TSC2 tumor suppressor genes,
which appear to act together as a complex of the encoded
proteins hamartin (TSC1) and tuberin (TSC2) (van Sleg-
tenhorst et al., 1998). At least 1 in 6,000 newborns carries
 
a constitutional TSC1 or TSC2 mutation and develops
tumors in the brain, kidneys, skin, or other organs (Young
and Povey, 1998). Although malignancy seldom develops,
the effects of the disease can be devastating, including mental
retardation, epilepsy, autism, pulmonary failure, kidney dys-
function, and disfigurement (Gomez et al., 1999). Because
deficiency in either TSC1 or -2 leads to a very similar disease
phenotype in humans with TSC (Jones et al., 1999), and
hamartin and tuberin form a complex in both mammalian
cells (van Slegtenhorst et al., 1998) and in 
 
Drosophila
 
 (Gao
and Pan, 2001; Potter et al., 2001), an important common
function of the TSC1-2 complex has been sought that could
explain its tumor suppressor activity. Individually, hamartin
contains a COOH-terminal ezrin-radixin-moesin–binding
domain and has been implicated in signaling to the actin
cytoskeleton (Lamb et al., 2000), whereas tuberin has an
NH
 
2
 
-terminal leucine zipper necessary for hamartin binding
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(Hodges et al., 2001), a COOH-terminal domain similar to that
found in GTPase-activating proteins (The European Chromo-
some 16 Tuberous Sclerosis Consortium, 1993), and may be
involved in membrane trafficking (Kleymenova et al., 2001).
The effects of TSC deficiency that could provide clues to
the functions of the TSC1-2 complex in mammalian tissues
have been hampered by the embryonic lethality caused by
homozygous TSC1 or -2 deficiency in knockout mice
(Kobayashi et al., 1999, 2001; Onda et al., 1999; Kwiat-
kowski et al., 2002). However, recent studies in 
 
Drosophila
 
have provided compelling evidence that the fly orthologues
of TSC1 and -2 regulate cell size both in larval and adult tis-
sues (Gao and Pan, 2001; Potter et al., 2001; Tapon et al.,
2001). Additional effects on the cell cycle in 
 
Drosophila
 
 were
also reported in these studies. These include an increase in
cell number and shortening of the G1 phase during eye
imaginal disc development (Tapon et al., 2001), as well as
inappropriate cell proliferation of post-mitotic cells (Potter
et al., 2001; Tapon et al., 2001). The effect of TSC defi-
ciency on cell size has been particularly amenable to genetic
epistasis analysis in the fly. This approach indicates that
TSC1-2 functions in insulin/phosphatidylinositide-3-OH
kinase (PI3K)–regulated signaling pathways, which control
cell size upstream of 
 
Drosophila
 
 p70 S6 kinase (S6K) (Gao
 
and Pan, 2001; Potter et al., 2001; Tapon et al., 2001).
Three models were proposed to explain the observed genetic
epistatic interactions between TSC1-2 and S6K (Potter et
al., 2001): (1) TSC1-2 is a direct downstream target of pro-
tein kinase B (PKB), until recently a presumed upstream
effector of mammalian target of rapamycin (mTOR) (Ra-
dimerski et al., 2002); (2) TSC1-2 acts on a parallel path-
way that integrates the insulin signaling pathway at the level
of S6K; or (3) TSC1-2 acts on a common downstream tar-
get of S6K. Here we provide evidence of a biochemical link
between TSC1-2 and S6K1, and establish that mTOR and
PI3K signaling act separately to activate S6K1, the latter by
repressing TSC1-2.
 
Results and discussion
 
TSC1-2 negatively regulates the phosphorylation 
and activity of S6K1
 
To address the relationship between TSC1-2 and S6K in
mammals, advantage was taken of mouse embryo fibroblasts
(MEFs) derived from mice deficient for TSC2 and a second
tumor suppressor gene, p53. Removal of p53 was required
for TSC2
 
 
 
/
 
 
 
 MEFs to proliferate in culture. Analysis of
S6K1 T389 phosphorylation and kinase activity in TSC2
 
 
 
/
 
 
Figure 1. The effects of TSC2 deficiency on the insulin signal transduction pathway. (a) Serum-deprived TSC2
 /  and TSC2
 /  MEFs were 
extracted directly or after stimulation with 200 nM insulin. S6K1 levels, T389 phosphorylation, and S6K1 activity were assayed as described 
previously (Dennis et al., 2001). (b) TSC2
 /  and
 TSC2
 /  MEFs and TSC
 /  MEFs stably transfected (left) with either wild-type ( WT) TSC2 or 
TSC2 N1643K ( N1643K) or G294E ( G294E) mutants were extracted after serum deprivation for 24 h. TSC2 levels were measured by 
Western blot analysis. S6K1 expression levels, T389 phosphorylation, and kinase activity were as in panel a. (c) TSC2
 /  MEFs were microinjected 
with empty pCMVTag vector (C) or the same vector encoding either wild-type TSC2 (WT) or N1643K or G294E mutants, and inhibition of 
S6K was detected using an antibody against phospho-S6 (Ser235/236). Arrows indicate microinjected cells. (d and e) Expression levels and 
phosphorylation of PKB and MAPK were measured by Western blot analysis after serum starvation or after stimulation for 30 min. 
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MEFs shows that both responses are constitutive and refrac-
tile to either mitogen withdrawal or stimulation by insulin
(Fig. 1 a). In control p53
 
 
 
/
 
 
 
 MEFs, both responses are basal
in the absence of mitogens and acutely stimulated by the ad-
dition of insulin (Fig. 1 a). Stable transfection or microinjec-
tion of wild-type human TSC2, but not either of two TSC
disease–associated point mutants, including a recently de-
scribed TSC2 mutant unable to bind TSC1 (Hodges et al.,
2001), restores regulated S6K1 T389 phosphorylation, ki-
nase activity, and S6 S235/S236 phosphorylation (Fig. 1, b
and c). These findings demonstrate that these effects are not
attributable to the absence of p53, and are consistent with
mutations thought to be the cause of TSC. To determine if
the effects of loss of TSC2 function were selective for the
S6K1 signaling pathway, the activities of MAPK and PKB
were also analyzed in the same cell lines by using phospho-
specific antibodies. The results show that serum stimulation
of MAPK phosphorylation was unaffected in TSC2
 
 
 
/
 
 
 
MEFs as compared with control MEFs (Fig. 1 d). However,
insulin-induced PKB S473 phosphorylation was strongly
suppressed in TSC2
 
 
 
 
 
/
 
 
 
 MEFs (Fig. 1 e) as was PKB activity
(see below). The effect of loss of TSC2 function on PKB ac-
tivation may reflect a recently described negative feedback
 
loop from mTOR/S6K to the PI3K signaling pathway
(Haruta et al., 2000), where rapamycin treatment leads to
increased signaling in the PI3K signaling pathway. Thus, in
the case of loss of TSC2 function, constitutive S6K1 signal-
ing may be expected to act in the opposite manner to inhibit
signaling in the PI3K pathway, such that PKB activity is
largely suppressed in TSC2-deficient cells. Taken together,
the results support a model whereby TSC1-2 operates as an
upstream negative effector of S6K1, rather than affecting a
common downstream target.
 
The translational inhibitor 4E-BP1 is regulated by TSC1-2
 
Phosphorylation of T389 of S6K1 is mediated by mTOR
(Burnett et al., 1998), as is the phosphorylation of the trans-
lation inhibitor, initiation factor 4E binding protein, 4E-
BP1 (Brunn et al., 1997). Analysis of 4E-BP1 in serum-
deprived TSC2
 
 
 
/
 
 
 
 MEFs indicates that 4E-BP1 is highly
phosphorylated, as judged by its qualitatively reduced elec-
trophoretic mobility, whereas the less highly phosphorylated
derivatives of 4E-BP1 are detectable in control MEFs (Fig. 2
a). Consistent with this interpretation, 4E-BP1 is not associ-
ated with translational initiation complexes containing
7-methyl cap–bound eIF4E from extracts of TSC2
 
 
 
/
 
 
 
 MEFs,
Figure 2. Inhibition of 4E-BP1, S6K1, and proliferation by rapamycin in TSC2
 /  and TSC2
 /  MEFs. (a) Serum-starved MEFs were extracted 
directly or after stimulation with 200 nM insulin in the absence or presence of 20 nM rapamycin. Phosphorylation of 4E-BP1, 4E-BP1 association 
with 7-methyl cap–bound eIF4E, and eIF4E levels were measured by Western blot analysis as previously described (von Manteuffel et al., 
1997). (b) S6K1 levels, T389 phosphorylation, and kinase activity were as in Fig. 1 a. (c) Proliferation of TSC2
 /  and TSC2
 /  MEFs was 
determined by culturing MEFs for the indicated times in the absence or presence of 1 nM rapamycin. Each value represents the average number 
of cells from three independent experiments, with the cell number from each culture determined by counting three independent dishes. Filled 
diamonds, TSC2
 / , untreated; filled triangles, TSC2
 /  with 1 nM rapamycin; filled circles, TSC2
 / , untreated; filled squares, TSC2
 /  with 
1 nM rapamycin. (d) Dual phase contrast and anti-BrdU–labeled nuclei (red) images of TSC2
 /  and TSC2
 /  MEFs left untreated for 4 d (UN, 
top) or in the presence of 1 nM rapamycin (Rapamycin, bottom). Inset shows percentage of BrdU-positive nuclei. 
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but is clearly present in extracts from control MEFs (Fig. 2
a). Insulin stimulation has no further effect on either phos-
phorylation or activity of 4E-BP1 in TSC2
 
 
 
/
 
 
 
 MEFs, but
leads to increased phosphorylation of 4E-BP1 and its release
from eIF4E in control MEFs (Fig. 2 a). In contrast, rapamy-
cin treatment of either cell type in the absence or presence of
insulin leads to 4E-BP1 dephosphorylation and its reassocia-
tion with eIF4E (Fig. 2 a). Similarly, rapamycin treatment
induces S6K1 T389 dephosphorylation and kinase inactiva-
tion in both TSC2-expressing or -deficient cells treated with
and without insulin (Fig. 2 b).
In parallel, we examined the effect of rapamycin on the
proliferation of TSC2
 
 
 
/
 
 
 
 and control MEFs. The results
show that TSC2
 
 
 
/
 
 
 
 MEFs grow more rapidly than control
MEFs, but that they are strikingly more sensitive to inhibi-
tion of proliferation by rapamycin (Fig. 2 c). Similar results
were obtained by examining the proportion of cycling cells
by BrdU labeling after treatment with low concentrations of
rapamycin (Fig. 2 d). These findings indicate that TSC2
negatively regulates the activity and phosphorylation of both
S6K1 and 4E-BP1 to restrict proliferation in normal cells.
 
TSC1-2 acts independently of mTOR on GST-
 
 
 
C-S6K1
 
That both S6K1 and 4E-BP1 are constitutively phosphory-
lated in TSC2
 
 
 
/
 
 
 
 MEFs and sensitive to rapamycin, argues
that TSC1-2 may act directly to inhibit mTOR function.
However, these findings do not exclude the possibility that
TSC1-2 functions either in a parallel pathway or down-
stream of mTOR to regulate the activities of both S6K1 and
4EBP-1. If TSC1-2 acts as a negative regulator of S6K1
through inhibiting mTOR function, S6K1 inactivation by
TSC1-2 overexpression should occur in an mTOR-depen-
dent manner. To test this, we first developed an assay in
which epitope-tagged variants of human TSC1 and TSC2
were ectopically expressed in Cos cells together with a wild-
type S6K1 reporter. Under these conditions, expression of
TSC1-2 reduced basal and insulin-induced S6K1 reporter
T389 phosphorylation and kinase activation (Fig. 3 a). In
Figure 3. The inhibitory effects of TSC1-2 on wild-type S6K1 and GST- C-S6K1. (a) Cos cells were cotransfected with S6K1 and Flag-tagged 
TSC1 and TSC2 expression constructs, and after serum deprivation, left untreated or stimulated with 200 nM insulin for 30 min. (b) Cos cells 
were cotransfected with S6K1 and TSC1 alone, TSC2 alone, TSC1 and wild-type TSC2 together, or TSC1 and N1643K TSC2 mutant together. 
Cells were extracted after stimulation with 200 nM insulin. Expression levels of S6K1 as well as T389 phosphorylation and kinase activity were 
determined as in Fig. 1. TSC1 and TSC2 were detected with a Flag epitope antibody. (c) Cos cells transfected with GST– C-S6K1 (Dennis et 
al., 2001) were stimulated with 200 nM insulin alone or in the presence of either 100 nM wortmannin or 20 nM rapamycin. (d) Cos cells were 
cotransfected with GST– C-S6K1 together with TSC1 and -2 and stimulated with insulin (Fig. 3 a). Expression levels of TSC1 and TSC2, S6K1 
phosphorylation, and activity of S6K were as in panel b. (e) TSC2
 /  MEFs microinjected with pCMVTag empty control vector (C) or pCMVTag 
vector encoding wild-type TSC2 (TSC2) in combination with expression vectors encoding GST-tagged wild-type S6K1 ( S6K1) or GST– C-S6K1 
after 12 h serum starvation (Serum-starved) alone or followed by treatment with 10 nM rapamycin (Serum starved   Rapamycin). Images are 
of cells expressing GST-tagged kinases ( -GST, green) and S6K1 activity measured using an antibody to phospho-S6 ( -pS6, red). 
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contrast, in a separate experiment, cotransfection of either
TSC1 or TSC2 alone or the human TSC2 N1643K mutant
(Fig. 1 b) with TSC1 had no significant effect on insulin-
induced S6K1 activation (Fig. 3 b). To determine whether in-
hibition of S6K1 by TSC1-2 was mTOR dependent, advan-
tage was taken of a recently described variant of S6K1,
GST–
 
 
 
C-S6K1, in which the COOH-terminal autoinhibi-
tory domain has been deleted and GST fused to the NH
 
2
 
terminus (Dennis et al., 2001). Consistent with earlier find-
ings, insulin-induced GST–
 
 
 
C-S6K1 T389 phosphory-
lation and activation are sensitive to the PI3K inhibitor
wortmannin, but resistant to rapamycin, and therefore un-
coupled from mTOR (Fig. 3 c). Unexpectedly, using the
Cos cell overexpression assay, coexpression of TSC1 and
wild-type TSC2 also suppressed insulin-induced GST–
 
 
 
C-
S6K1 reporter T389 phosphorylation and activation (Fig. 3
d), and thus phenocopied wortmannin but not rapamycin
treatment. To confirm these results, we used an alternative
assay in which TSC1-2 regulates S6K1. Because reintroduc-
tion of wild-type TSC2 by microinjection into TSC2
 
 
 
/
 
 
 
MEFs restores serum-regulated S6K1 activity, presumably
through forming complexes with endogenous TSC1 (Fig. 1,
b and c), we reasoned that it may similarly regulate the activ-
ity of either ectopically expressed S6K1 or GST–
 
 
 
C-S6K1.
However, given the findings above we would expect GST–
 
 
 
C-S6K1 to be resistant to the effects of rapamycin. Indeed,
introduction of TSC2 together with either S6K1 or GST–
 
 
 
C-S6K1 led to kinase inhibition in serum-derived TSC2
 
 
 
/
 
 
 
MEFs in the presence or absence of rapamycin as assessed
by phospho-S6 staining (Fig. 3 e). In contrast, only GST–
 
 
 
C-S6K1 was active when introduced with control vector in
the presence of rapamycin, confirming that this S6K1 vari-
ant is indeed mTOR independent, but still regulated by
TSC2. Taken together, these findings argue that TSC1-2 in-
hibition of S6K1 is unlikely to be via direct regulation of
mTOR.
 
PI3K signaling antagonizes S6K1 inhibition 
by TSC1-2 in normal cells
 
The results above show that insulin stimulation of the rapa-
mycin-resistant variant of S6K1 is inhibited to approxi-
mately the same extent by either wortmannin or TSC1-2
overexpression (Fig. 3, b and c), raising the possibility that
TSC1-2 inhibition of S6K1 is suppressed by insulin-induced
PI3K activation. Consistent with this model, in most mam-
malian cell types, S6K1 activation is blocked by either the
PI3K inhibitor wortmannin or by dominant interfering alle-
les of PI3K (Reif et al., 1997). To test whether TSC1-2 re-
pression is mediated by PI3K, both TSC2
 
 
 
/
 
 
 
 and control
MEFs were treated with wortmannin in the absence or pres-
ence of insulin (Fig. 4 a). In the absence of insulin stimula-
tion, increased T389 phosphorylation and S6K1 activity are
unaffected by wortmannin treatment in TSC2
 
 
 
/
 
 
 
 MEFs
(Fig. 4). Likewise, wortmannin has little affect on either re-
sponse in these same cells in the presence of insulin, but both
responses are blocked by the drug in control cells (Fig. 4 a),
implying that the role of PI3K in S6K activation in normal
cells may be to repress TSC1-2. Consistent with wortman-
nin inhibiting PI3K signaling, and the specificity of TSC1-2
for S6K1, treatment of either cell type with the drug abol-
 
ished PKB S473 phosphorylation (Fig. 4 b) and kinase activ-
ity using the synthetic peptide Crosstide (Cross et al., 1995)
as a substrate in an immune complex assay (Fig. 4 c).
These findings raised the possibility that in normal cells,
TSC1-2 might also regulate 4E-BP1 phosphorylation in a
PI3K-dependent manner. To test this, we examined the effect
of wortmannin on the phosphorylation status of 4E-BP1 and
its association with initiation factor eIF4E in both TSC2-
expressing or -deficient MEFs in the absence and presence of
insulin. The results show that wortmannin has no effect on
the maximally phosphorylated state of 4E-BP1 in either un-
treated or insulin-treated TSC2
 
 
 
/
 
 
 
 MEFs, or on its interac-
tion with initiation factor eIF4E (Fig. 4 d). In contrast, insu-
lin-induced 4E-BP1 phosphorylation and its release from
initiation factor 4E are abolished by wortmannin treatment
in control MEFs (Fig. 4 d). Consistent with these findings,
microinjection of either kinase-inactive PI3K or a deletion
mutant of the PI3K p85 subunit blocks S6 S235/S236 phos-
phorylation in control MEFs, but not in TSC2
 
 
 
/
 
 
 
 MEFs
(Fig. 4 e). These results indicate that constitutive S6K1 activ-
ity in TSC2-deficient cells is not due to deregulated PI3K sig-
naling, and support a model whereby in normal cells PI3K
mediates insulin-induced S6K1 and 4E-BP1 phosphorylation
through repressing TSC1-2 function (Fig. 4 f).
 
TSC1-2 mechanism of action in regulating 
S6K1 and 4E-BP1
Mitogen-induced S6K1 activation is mediated by the phos-
phorylation of residues residing in its linker and conserved
catalytic domains in a hierarchical manner via mTOR and
the phosphoinositide-dependent protein kinase 1, respec-
tively (Isotani et al., 1999). Despite prevailing models that
both kinases are downstream effectors of PI3K with respect
to S6K1 activation (Blume-Jensen and Hunter, 2001), recent
studies indicate that this is not the case for either kinase
(Pullen et al., 1998; Dennis et al., 2001). Instead, both ki-
nases appear constitutively active regardless of mitogenic
ligand stimulation. Our findings demonstrate that in normal
cells the PI3K input to S6K1 is the suppression of TSC1-2,
which we hypothesize may normally act as a positive effector
of a S6K1 phosphatase. Alternatively, given the potential
role of TSC2 in trafficking to the plasma membrane (Kley-
menova et al., 2001), TSC1-2 complexes may act to parti-
tion S6K1 in a compartment of the cell where access by acti-
vating kinases is limited.
However, it also should be noted that in a few cell types
and in Drosophila (Radimerski et al., 2002), S6K1 activation
can be PI3K independent, suggesting other mechanisms
may exist to regulate TSC1-2 function. During the comple-
tion of these studies, others reported that S6K1 activity was
elevated in TSC1-deficient cells and blocked by rapamycin
and LY294002 (Kwiatkowski et al., 2002), a PI3K inhibitor
(Vlahos et al., 1994). This led to the conclusion that PI3K
induces S6K1 activation through mTOR and that mTOR is
the target of TSC1-2 suppression. However, at the concen-
trations employed, LY294002 has been demonstrated to be
a potent inhibitor of both PI3K and mTOR (Brunn et al.,
1996). Thus, the fact that LY294002 inhibits phosphoryla-
tion of S6K1 in TSC1-deficient cells is most likely explained
by inhibitory affects of the drug on mTOR rather than222 The Journal of Cell Biology | Volume 159, Number 2, 2002
PI3K. Such an explanation would clarify why we observe lit-
tle to no inhibitory affect of wortmannin or microinjection
of either a kinase-inactive PI3K or a deletion mutant of the
p85 subunit on S6K1 activity.
Our findings indicate that in normal cells, signaling via
PI3K antagonizes the TSC1-2 complex and its ability to re-
press S6K1. During the review process, three other reports
have appeared that suggest a mechanism of the PI3K-regu-
lated TSC1-2 inactivation described here. Activation of the
PI3K-regulated serine-threonine kinase Akt/PKB has been
shown in these studies to lead to phosphorylation of TSC2
(Inoki et al., 2002; Manning et al., 2002; Potter et al.,
Figure 4. The repression of S6K1 and 4E-BP1 by TSC1-2 is mediated by PI3K. (a) TSC2
 /  and TSC2
 /  MEFs were extracted directly or after 
stimulation in the absence or presence of 100 nM wortmannin. Expression of S6K1, T389 phosphorylation, and S6K1 activity were measured 
as in Fig. 1. (b) Expression and phosphorylation of PKB were determined as in Fig. 1 c. (c) Activity measurement of PKB was analyzed as 
described previously (Pullen et al., 1998). (d) 4E-BP1 phosphorylation and levels of eIF4E were as described in Fig. 2 b. (e) TSC2
 /  and TSC2
 /  
MEFs were microinjected with expression plasmids encoding either an empty pCMVTag vector (C; top), a p85 deletion mutant ( p85; middle), 
or a kinase-inactive PI3K (p110KD; bottom). S6 phosphorylation was detected using an antibody against phospho-S6. (f) Model showing that 
PI3K mediates insulin induction of S6K1 and 4E-BP1 through repression of TSC1-2. TSC tumor suppressor regulates S6K1 and 4E-BP1 | Jaeschke et al. 223
2002), although the suggested mechanism of the resulting
inhibition of the TSC1-2 complex varies between studies.
Interestingly, these new reports place Akt/PKB upstream of
S6K1, despite previous data to the contrary (Dufner et al.,
1999, Radimerski et al., 2002). Further studies are clearly
necessary to establish whether inactivation of TSC1-2 by the
activated alleles of Akt/PKB commonly used in these types
of studies is equivalent to physiological ligand-induced acti-
vation of PI3K signaling for S6K1 regulation. More impor-
tantly, it will be critical to establish whether such a mode of
inactivation of the TSC1-2 complex by phosphorylation in
normal cells is equivalent to the mode of inactivation of
TSC1-2 by pathogenic TSC2 mutations. Finally, in one of
these reports (Inoki et al., 2002), use of different rapamycin-
resistant S6K1 constructs has allowed the authors to reach
opposite conclusions from ours regarding whether TSC1-2
regulates S6K1 by regulating mTOR activity, or acts directly
on S6K1. With the emerging importance of the mTOR–
S6K–4E-BP signaling pathway in cancer (Gingras et al.,
2001), it will be critical to resolve this issue and establish the
molecular mechanisms by which TSC1-2 acts as a tumor
suppressor in this pathway. Importantly, given the selective
effects of rapamycin on the proliferation of TSC2
 /  MEFs
described here and its efficacious use in the treatment of
solid tumors in phase 1 clinical trials (Hidalgo and Rowin-
sky, 2000), the use of this drug could be explored for the
treatment of TSC and TSC-associated maladies.
Materials and methods
MEF cell lines
Mouse embryonic fibroblast lines from Tsc2
 / ;p53
 /  and Tsc2
 / ;p53
 / 
embryos will be described elsewhere (provided by H. Onda and D. Kwiat-
kowski, Brigham and Women’s Hospital, Boston, MA). In brief, E10–10.5
embryos were collected from Tsc2
 / ;p53
 /  intercrosses. The stage of em-
bryos were estimated by counting days after vaginal plug was observed in
female (considered to be E0.5) and confirmed by developmental stage of
limb bud at the time of harvesting. Embryo viability was determined
by cardiac contraction, however, in some cases nonviable “embryoid
masses” are also used. Each embryo was triturated in DME, and then
plated in DME supplemented with 10% FBS, 50  g/ml penicillin, and 50
 g/ml streptomycin in 5% CO2. MEF cultures from each embryo were ex-
panded and the genotype of each culture was initially determined by PCR
of DNA isolated from extraembryonic membrane and further confirmed by
Western blotting for tuberin expression in the cultured cells. All experi-
ments were performed at early passages ( 20). When possible, all experi-
ments were performed on paired littermates. For measurement of prolifera-
tion, MEFs were seeded at 0.5   10
4 per 9-cm dish and cells were counted
every second day for 6 d with rapamycin added to 1  M every 2 d. For
BrdU labeling, cells were seeded at the same density on 24-mm glass cov-
erslips and 24 h later treated with 1  M rapamycin for 4 d, before labeling
with 5  g/ml BrdU (Sigma-Aldrich) for 8 h. Cells were subsequently fixed
and stained with a rat anti-BrdU monoclonal antibody and Hoechst to vi-
sualize cell nuclei. To count BrdU-positive cells, the total number of nu-
clei and BrdU-positive nuclei were counted in each of three 10  objective
fields for each MEF line and condition and numbers averaged to give a
percentage. Dual phase contrast and BrdU-positive images were obtained
from 10  fields using Axiovision and Adobe Photoshop
® software.
Transfection and retroviral reintroduction of TSC2 
into TSC2
 /  MEFs
For transient transfection of Cos cells, cells were seeded in 6-well plates at
2   10
5 per well. Transfection was performed using Fugene 6 from Roche.
24 h after transfection, cells were serum starved for 48 h and extracted di-
rectly or after stimulation with 200 nM insulin, with or without the addi-
tion of 20 nM rapamycin or 100 nM wortmannin. For retroviral transfec-
tion, the complete coding regions of wild-type TSC2 and the TSC N1643K
and G294E mutants were excised as BamH1 fragments from pCMVTag2
TSC2 vectors and cloned into a modified retroviral vector based on
pRevTRE (CLONTECH Laboratories, Inc.), in which the TRE-minimal CMV
promoter was replaced with the minimal tk promoter from pBLCAT2.
BOSC cells were used to package retroviruses and retroviral supernatants
used to infect TSC2
 / /p53
 /  MEFs. Retrovirally transduced populations
were selected with hygromycin and 3T3 cell lines generated by limit dilu-
tion cloning.
Microinjection
TSC2
 /  or TSC2
 /  MEFs on coverslips were nuclear microinjected with
0.1 mg/ml plasmids together with 5 mg/ml biotin–dextran (Molecular
Probes) as an injection marker. For Fig. 1 c, TSC
 /  MEFs were microin-
jected with 0.2 mg/ml empty pCMVTag vector or the same vector express-
ing wild-type TSC2 or TSC2 mutants. For Fig. 2 e, cells were injected with
0.5 mg/ml pCMVTag empty vector or pCMVTag wild-type TSC2 together
with 0.1 mg/ml pRK5-GSTS6K1 or 0.3 mg/ml pRK5-GST– C-S6K1. In both
Fig. 1 c and Fig. 3 e, cells were serum starved after microinjection for 12 h
and left untreated or treated with 10 nM rapamycin for a further 1 h before
fixation. Expression of S6K1 was detected using a monoclonal antibody to
GST (Santa Cruz Biotechnology, Inc.) and goat anti–mouse FITC. For Fig. 4
e, empty pCMVTag vector or expression plasmids encoding PI3K deltap85
(pcDNA3) or kinase-dead p110 (pEFBos; both from Dr. Julian Downward)
were injected at 0.1 mg/ml. After serum starvation for 12 h, TSC2
 /  were
left unstimulated whereas TSC2
 /  cells were stimulated with 200 nM in-
sulin for 1 h before fixation. All cells were fixed for 15 min with 4% para-
formaldehyde in PBS, permeabilized for 10 min with PBS/0.4% Triton
X-100, blocked for 15 min with PBS/1% BSA, and stained with an antibody
to phospho-S6 (Ser235/236; Cell Signaling) followed by goat anti–rabbit
TRITC (Molecular Probes). Injected cells were detected with Alexa
®350-
conjugated Streptavidin (Molecular Probes). Images were acquired on a
ZEISS Axioplan 2 imaging microscope on 20  or 40  objectives with Ax-
iovision software and processed either as greyscale or dual color TIFF im-
ages in Adobe Photoshop
®.
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